Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group
Annals of Hematology · 01.08.2026 · 105 (11)
DOI: 10.1007/s00277-026-07039-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 01.08.2026. Verfasst von R De Paz Arias und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Aniline Compounds, Nitriles, Quinolines, Protein Kinase Inhibitors. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Treatment-free remission (TFR) is an established therapeutic goal for patients with chronic myeloid leukemia (CML) achieving sustained deep molecular response (DMR) on tyrosine kinase inhibitors (TKIs). However, evidence on TFR following bosutinib discontinuation remains limited. BOSUTFR is a multicenter, retrospective study by the Spanish CML Group (GELMC) evaluating TFR feasibility after bosutinib cessation in patients with chronic-phase CML. Twenty-five adults from 15 centers who maintained ≥MR4.0 for at least 2 years or discontinued for intolerance were included. The primary endpoint was TFR rate at 12 months. Thirteen patients (52%) stopped treatment after sustained MR4.0 and 12 (48%) due to intolerance, including 2 patients from fifth-line therapy. After a median follow-up of 4.6 years, 17/25 (68.0%) maintained TFR, with TFR rates at 12 and 24 months of 70.4% and 64.5%. No disease progressions or deaths occurred. All patients with molecular recurrence regained DMR after restarting bosutinib (n = 6) or switching to asciminib (n = 2). Median duration of bosutinib therapy before discontinuation was 4.5 years, and median DMR duration was 36 months. Notably, 9 of 11 patients (81.8%) who discontinued due to intolerance remained in TFR, including 4 of 5 who stopped in MMR. This is the largest real-world cohort of bosutinib discontinuations to date. Results confirm that bosutinib discontinuation is feasible and safe in real-world practice, including for patients who discontinue for intolerance, heavily pretreated patients, and patients with less stringent molecular response criteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario La Paz, Madrid, Spain.
- Hospital Universitario de Gran Canaria Dr. Negrín, Instituto de Investigación Sanitaria de Canarias, Las Palmas, Spain. rstuckey@fciisc.es.
- Hospital Universitario Quirónsalud, Zaragoza, Spain.
- Institut Català d' Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
- University Hospital 12 de Octubre; i+12; CNIO; Universidad Complutense de Madrid, Madrid, Spain.
- University Hospital Puerta de Hierro, Madrid, Spain.
Förderung
- Pfizer
Zitieren
APA
De Paz Arias, R., Maortua Langdon, G., Stuckey, R., Giraldo, P., Xicoy, B., Martínez López, J., Bautista, G., Alonso Alonso, J. M., Noya, M. S., Sierra, M., de Las Heras, N., Pérez López, R., Saavedra, S., Gómez-García de Soria, V., Chen-Liang, T. H., Santaliestra, M., García Gutiérrez, V., & Spanish CML Group (GELMC) (2026). Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07039-4
Vancouver
De Paz Arias R, Maortua Langdon G, Stuckey R, Giraldo P, Xicoy B, Martínez López J, et al. Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07039-4
BibTeX
@article{DePazArias2026,
author = {De Paz Arias, R and Maortua Langdon, G and Stuckey, R and Giraldo, P and Xicoy, B and Martínez López, J and Bautista, G and Alonso Alonso, J M and Noya, M S and Sierra, M and de Las Heras, N and Pérez López, R and Saavedra, S and Gómez-García de Soria, V and Chen-Liang, T H and Santaliestra, Marta and García Gutiérrez, V and Spanish CML Group (GELMC), Spanish CML Group (GELMC)},
title = {Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07039-4}
}
EUVIMED